Article

Synthesis and Evaluation of 68Ga- and 177Lu-Labeled [diF-Pro14]Bombesin(6–14) analogs for Detection and Radioligand Therapy of Gastrin-Releasing Peptide Receptor-Expressing Cancer

Lei Wang , Chao-Cheng Chen , Devon Chapple , Antonio A. W. L. Wong , Sara Kurkowska , Wing Sum Lau , Carlos F. Uribe , François Bénard , Kuo-Shyan Lin [*]

Article

Synthesis and Evaluation of ^{68}Ga- and ^{177}Lu-Labeled [diF-Pro^{14}]Bombesin(6–14) Analogs for Detection and Radioligand Therapy of Gastrin-Releasing Peptide Receptor-Expressing Cancer

Lei Wang [1], Chao-Cheng Chen [1], Devon Chapple [1], Antonio A. W. L. Wong [1], Sara Kurkowska [2,3], Wing Sum Lau [1], Carlos F. Uribe [2,4,5], François Bénard [1,4,5] and Kuo-Shyan Lin [1,4,5,*]

[1] Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada

[2] Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada

[3] Department of Nuclear Medicine, Pomeranian Medical University, Szczecin 70-204, Poland

[4] Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, BC V5Z 4E6, Canada

[5] Department of Radiology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada

* Correspondence: klin@bccrc.ca; Tel.: +1-604-675-8208

Abstract: Overexpressed in various solid tumors, gastrin-releasing peptide receptor (GRPR) is a promising target for cancer diagnosis and therapy. However, high pancreas uptake of current clinically evaluated GRPR-targeted radiopharmaceuticals limits their applications. In this study, we replaced the Pro^{14} residue in our previously reported GRPR-targeted LW02056 and ProBOMB5 with 4,4-difluoroproline (diF-Pro) to obtain an agonist LW02060 (DOTA-Pip-[D-Phe^6,Tle^{10},NMe-His^{12},diF-Pro^{14}]Bombesin(6-14)) and an antagonist LW02080 (DOTA-Pip-[D-Phe^6,NMe-Gly^{11},Leu^{13}(ψ)diF-Pro^{14}]Bombesin(6-14)), respectively. The binding affinities (K$_i$) of Ga-LW02060, Ga-LW02080, Lu-LW02060, and Lu-LW02080 were measured by in vitro competition binding assays using PC-3 cells and were 5.57 ± 2.47, 21.7 ± 6.69, 8.00 ± 2.61, and 32.1 ± 8.14 nM, respectively. The ^{68}Ga- and ^{177}Lu-labeled ligands were obtained in 36 - 75% decay-corrected radiochemical yields with > 95% radiochemical purity. PET imaging, SPECT imaging, and ex vivo biodistribution studies were conducted in PC-3 tumor-bearing mice. Both [^{68}Ga]Ga-LW02060 and [^{68}Ga]Ga-LW02080 enabled clear tumor visualization in PET images at 1 h post-injection (pi). Tumor uptake values of [^{68}Ga]Ga-LW02060 and [^{68}Ga]Ga-LW02080 at 1 h pi were 16.8 ± 2.70 and 7.36 ± 1.33 %ID/g, respectively, while their pancreas uptake values were 3.12 ± 0.89 and 0.38 ± 0.04 %ID/g, respectively. Compared to [^{177}Lu]Lu-LW02080, [^{177}Lu]Lu-LW02060 showed higher tumor uptake at all time points (1, 4, 24, 72 and 120 h pi). However, fast tumor clearance was observed for both [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080. Our data demonstrate that [^{68}Ga]Ga-LW02060 is promising for clinical translation for the detection of GRPR-expressing tumor lesions. However, further optimizations are needed for [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080 to prolong tumor retention for therapeutic applications.

Keywords: gastrin-releasing peptide receptor; 4,4-difluoroproline; gallium-68; lutetium-177; pancreas uptake

1. Introduction

Gastrin-releasing peptide receptor (GRPR) is a member of G-protein coupled receptors and is expressed in human body including pancreas, gastrointestinal tract, and central nervous system [1,2]. It is involved in regulating many physiological functions, such as hormone secretion, smooth muscle contraction, and synaptic plasticity [1,2]. Furthermore, GRPR is found significantly overexpressed in various solid malignancies, including breast, prostate, lung, and colon cancers, where it functions as

a tumor growth factor [3–8]. Such characteristics of GRPR makes it a promising target for the design of targeted radiopharmaceuticals for diagnosis and radioligand therapy of GRPR-expressing cancer.

Bombesin (BBN) is a natural peptide showing very potent binding affinity to GRPR. Its *C*-terminal heptapeptide, bombesin(8-14), has been identified as the sequence needed for binding to GRPR and is widely utilized for the design of GRPR-targeted pharmaceuticals [9–16]. However, most clinically evaluated GRPR-targeted radiopharmaceuticals derived from BBN showed extremely high pancreas uptake, which not only limits the detection of GRPR-expressing tumor lesions in and near pancreas but also lowers the maximum tolerated dose for radiotherapeutic applications [9–14,17]. Moreover, enzymatic degradation by neutral endopeptidase 24.11 (NEP, EC 3.4.24.11, neprilysin) results in low in vivo stability for most of reported GRPR-targeted radiopharmaceuticals derived from the BBN sequence [18,19].

To address these two major limitations, our group previously developed a series of GRPR-targeted radiopharmaceuticals [20,21]. These ligands were derived from RC-3950-II ([D-Phe[6],Leu[13](ψ)Thz[14]]Bombesin(6-14)), which has a Thz[14] (thiazoline-4-carboxylic acid) substitution and a reduced peptide bond (CH_2-N) between residues 13-14 (Leu[13](ψ)Thz[14]) [15,16]. All the ^{68}Ga-labeled GRPR antagonists derived from the [Leu[13](ψ)Thz[14]]Bombesin(6-14) pharmacophore and all the ^{68}Ga-labeled GRPR agonists derived from the [Thz[14]]Bombesin(6-14) pharmacophore showed low pancreas uptake (0.78 - 7.26%ID/g at 1 h post-injection (pi)) [20,21]. Subsequently, our group improved in vivo stability of the lead candidates by systematically substituting natural amino acids at potential cleavage sites (Gln[7], Trp[8], Ala[9], Val[10], Gly[11] and His[12]) with unnatural amino acids. This led to the discoveries of several GRPR-targeted radiopharmaceuticals with significantly improved in vivo stability [22,23]. We discovered that Tle[10] and NMe-His[12] substitutions either in combination or alone can significantly enhance the in vivo stability and improve the tumor uptake of ^{68}Ga-labeled GRPR agonists derived from the [Thz[14]]Bombesin(6-14) pharmacophore [22]. We also identified that NMe-Gly[11] substitution can improve the tumor uptake and tumor-to-organ uptake ratios of ^{68}Ga-labeled GRPR antagonists derived from the [Leu[13](ψ)Thz[14]]Bombesin(6-14) pharmacophore [20,23]. Recently, we reported two novel GRPR-targeted ligands, LW02056 and ProBOMB5 (Figure 1), by replacing the Thz[14] in our previously identified LW01110 and TacsBOMB5, respectively, with Pro[14] to avoid oxidation of Thz in the product formulation [24]. Though a slight reduction was observed for the tumor uptake of [^{68}Ga]Ga-LW02056 (8.93 ± 1.96 %ID/g at 1 h pi), it had very low pancreas uptake (1.31 ± 0.42 %ID/g at 1 h pi) and good tumor-to-background imaging contrast [24]. The Pro[14]-derived antagonist, [^{68}Ga]Ga-ProBOMB5, showed good tumor uptake (12.4 ± 1.35 %ID/g), low pancreas uptake (1.37 ± 0.40 %ID/g), and excellent tumor-to-background imaging contrast at 1 h pi [24].

Fluorinated proline derivatives play a crucial role in peptide engineering and drug discovery due to their resistance to degradation by proteases and their ability to modulate polarity and lipophilicity [25,26]. A 4,4-difluoroproline (diF-Pro) derivative, 4,4-difluoropyrrolidine-2-carbonitrile, has been successfully introduced in the design of potent fibroblast activation protein (FAP) inhibitors to mimic Pro [27], and now 4,4-difluoropyrrolidine-2-carbonitrile is widely used for the design of FAP-targeted radiopharmaceuticals [28]. In this study, we synthesized two GRPR-targeted ligands, LW02060 and LW02080, by replacing Pro[14] of LW02056 and ProBOMB5, respectively, with diF-Pro[14] (Figure 1). Subsequently, we characterized the antagonist/agonist characteristics of these two ligands and their Ga/Lu-complexed analogs. We also assessed their potential for PET imaging and targeted radiotherapy using a preclinical tumor model derived from GRPR-expressing PC-3 prostate cancer cells. We hypothesized that (1) diF-Pro[14] substitution would retain GRPR agonist/antagonist characteristics and good binding affinity to GRPR; (2) compared with their Pro[14] analogs, the diF-Pro[14]-derived radioligands would have comparable or even higher in vivo stability, and could be promising for detection and radioligand therapy of GRPR-expressing malignancies.

Figure 1. Chemical structures of (A) LW02056 and LW02060, (B) ProBOMB5 and LW02080. Unnatural amino acid substitutions (Tle[10], NMe-Gly[11] and NMe-His[12]) are in blue and diF-Pro[14] is in brown.

2. Results

2.1. Chemistry and Radiochemistry

LW02060 and LW02080 were synthesized on solid phase using the Fmoc chemistry, and their isolated yields were 23% and 39%, respectively. The isolated yields for the synthesis of Ga-LW02060 and Ga-LW02080 were 87% and 93%, respectively, and the isolated yields for Lu-LW02060 and Lu-LW02080 were 87% and 90%, respectively (Tables S1-S2). ^{68}Ga-labeled LW02060 and LW02080 were obtained in 41 - 75% decay-corrected radiochemical yields with > 172 GBq/μmol molar activity and > 95% radiochemical purity (Table S3). ^{177}Lu-labeled LW02060 and LW02080 were obtained in 36 - 64% decay-corrected radiochemical yields with > 125 GBq/μmol molar activity and > 97% radiochemical purity (Table S3).

2.2. Agonist/Antagonist Characterization, Binding Affinity, and Hydrophilicity

All LW02060 and its Ga/Lu-complexed analogs were confirmed to be GRPR agonists, while all LW02080 and its Ga/Lu-complexed analogs were confirmed to be GRPR antagonists by intracellular calcium release assays using PC-3 cells (Figure 2). Fifty nM of LW02060, Ga-LW02060, Lu-LW02060, ATP (positive control), and bombesin (agonist control) induced Ca^{2+} efflux corresponding to 377 ± 41.9, 405 ± 58.3, 397 ± 43.4, 286 ± 9.44, and 371 ± 17.9 RFU (relative fluorescent unit), respectively. By contrast, 50 nM of LW02080, Ga-LW02080, Lu-LW02080 and [D-Phe[6],Leu-NHEt[13],des-

Met[14]]Bombesin(6-14) (antagonist control), and Dulbecco's phosphate-buffered saline (DPBS, blank control) induced Ca^{2+} efflux corresponding to only 11.4 ± 0.32, 12.4 ± 1.76, 10.8 ± 1.22, 16.6 ± 3.84, and 41.2 ± 5.40 RFU, respectively.


Figure 2. Intracellular calcium efflux in PC-3 cells induced by various tested ligands. Error bars indicate standard deviation (n = 4).

The binding affinities of Ga-LW02060, Ga-LW02080, Lu-LW02060, and Lu-LW02080 were determined by in vitro competition binding assays using GRPR-expressing PC-3 cells and [^{125}I-Tyr[4]]Bombesin as the radioligand. The binding of [^{125}I-Tyr[4]]Bombesin to PC-3 cells was inhibited by all tested ligands in a dose-dependent manner (Figure 3). The calculated K_i values for Ga-LW02060, Ga-LW02080, Lu-LW02060, and Lu-LW02080 were 5.57 ± 2.47, 21.7 ± 6.69, 8.00 ± 2.61, and 32.1 ± 8.14 nM, respectively (n = 3).


Figure 3. Displacement curves of [^{125}I-Tyr[4]]Bombesin by Ga-LW02060, Ga-LW02080, Lu-LW02060, and Lu-LW02080 generated using GRPR-expressing PC-3 cells. Error bars indicate standard deviation (n = 3).

The hydrophilicity of [^{68}Ga]Ga-LW02060, [^{68}Ga]Ga-LW02080, [^{177}Lu]Lu-LW02060, and [^{177}Lu]Lu-LW02080 were determined via the shake flask method, and the calculated $logD_{7.4}$ values were −2.57 ± 0.04, −2.60 ± 0.03, −2.45 ± 0.03, and −2.33 ± 0.26, respectively (n = 3).

2.3. PET Imaging and Ex Vivo Biodistribution

Both [^{68}Ga]Ga-LW02060 and [^{68}Ga]Ga-LW02080 were excreted mainly via the renal pathway and enabled clear visualization of the PC-3 tumor xenografts in PET images at 1 h pi as shown in Figure

4. Except tumor xenografts, kidneys and urinary bladder, the uptake of both tracers in other organs/tissues were minimal. [^{68}Ga]Ga-LW02060 showed a better tumor uptake, and both tracers had excellent tumor-to-background imaging contrast. Co-injection with 100 μg of [D-Phe^6,Leu-NHEt^{13},des-Met^{14}]Bombesin(6-14) or nonradioactive Ga-LW02080 significantly decreased the uptake of [^{68}Ga]Ga-LW02060 and [^{68}Ga]Ga-LW02080, respectively, in PC-3 tumor xenografts. The kidney uptake in both blocked mice were markedly increased.


Figure 4. Representative PET images of [^{68}Ga]Ga-LW02060 and [^{68}Ga]Ga-LW02080 acquired at 1 h pi in PC-3 tumor-bearing mice. The blocked mouse of [^{68}Ga]Ga-LW02060 was co-injected with 100 μg of [D-Phe^6,Leu-NHEt^{13},des-Met^{14}]Bombesin(6-14), and the blocked mouse of [^{68}Ga]Ga-LW02080 was co-injected with 100 μg of nonradioactive Ga-LW02080. t: tumor; k: kidney; bl: urinary bladder.

The ex vivo biodistribution studies for both [^{68}Ga]Ga-LW02060 and [^{68}Ga]Ga-LW02080 were conducted at 1 h pi in PC-3 tumor-bearing mice, and the results were consistent with the observations from the PET images (Figures 5 and 6 and Table S4). Compared to [^{68}Ga]Ga-LW02080, [^{68}Ga]Ga-LW02060 had a higher tumor uptake (7.36 ± 1.13 vs 16.8 ± 2.70 %ID/g, $p < 0.001$), leading to better tumor-to-bone and tumor-to-kidney uptake ratios (69.8 ± 13.7 vs 179 ± 46.9 and 3.18 ± 0.75 vs 4.86 ± 0.76, respectively). The pancreas uptake of [^{68}Ga]Ga-LW02060 was 3.12 ± 0.89 %ID/g, significantly higher than that of [^{68}Ga]Ga-LW02080 (0.38 ± 0.04 %ID/g, $p < 0.05$), resulting in a lower tumor-to-pancreas uptake ratio for [^{68}Ga]Ga-LW02060 (5.52 ± 0.78 vs 18.4 ± 2.86, $p < 0.001$). Furthermore, [^{68}Ga]Ga-LW02060 also showed significantly higher uptake in some normal organs than [^{68}Ga]Ga-LW02080 such as in small intestine, large intestine, and stomach. Consistent with the observations from PET images, moderate kidney uptake was obtained for [^{68}Ga]Ga-LW02060 (3.58 ± 1.14 %ID/g) and [^{68}Ga]Ga-LW02080 (2.42 ± 0.81 %ID/g). Except tumor xenografts and kidneys, the uptake values of [^{68}Ga]Ga-LW02060 and [^{68}Ga]Ga-LW02080 for all other collected organs/tissues were lower than 1 %ID/g.

Figure 5. (A) Uptake of [68Ga]Ga-LW02060 and [68Ga]Ga-LW02080 in PC-3 tumor xenografts and major organs/tissues of NRG mice at 1 h pi. Error bars indicate standard deviation; (B) Tumor-to-organ uptake ratios of [68Ga]Ga-LW02060 and [68Ga]Ga-LW02080 obtained from PC-3 tumor-bearing mice at 1 h pi. Error bars indicate standard deviation. *$p < 0.05$; **$p < 0.01$; ***$p < 0.001$.

Co-injection with 100 μg of [D-Phe6,Leu-NHEt13,des-Met14]Bombesin(6-14) significantly reduced the average uptake of [68Ga]Ga-LW02060 in PC-3 tumor xenografts by 64% (from 16.8 ± 2.70 %ID/g to 6.11 ± 0.42 %ID/g, $p < 0.001$) (Figure 6A and Table S4). Co-injection with 100 μg of nonradioactive Ga-LW02080 reduced the average tumor uptake of [68Ga]Ga-LW02080 by 77% (from 7.36 ± 1.13 %ID/g to 1.71 ± 0.39 %ID/g, $p < 0.001$) (Figure 6B and Table S4). Co-injection with a blocking agent also significantly increased the uptake of both tracers in most of the collected normal organs/tissues, especially in kidneys (from 3.58 ± 1.14 %ID/g to 11.3 ± 0.97 %ID/g for [68Ga]Ga-LW02060, $p < 0.001$; from 2.42 ± 0.81 %ID/g to 11.2 ± 1.02 %ID/g for [68Ga]Ga-LW02080, $p < 0.01$,) (Figure 6 and Table S4).

**Figure 6.** (A) Comparison of [^{68}Ga]Ga-LW02060 with/without co-injection of [D-Phe^6,Leu-NHEt^{13},des-Met^{14}]Bombesin(6-14) on the uptake in PC-3 tumor xenografts and major organs/tissues in mice at 1 h pi; (B) comparison of [^{68}Ga]Ga-LW02080 with/without co-injection of its nonradioactive standard on the uptake in PC-3 tumor xenografts and major organs/tissues in mice at 1 h pi. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.

2.4. In Vivo Stability

The in vivo stability of [^{68}Ga]Ga-LW02060 and [^{68}Ga]Ga-LW02080 was evaluated in NRG mice (n = 3) (Figures 7 and 8). There was > 99% of [^{68}Ga]Ga-LW02060 remaining intact in plasma at 15 min pi, which was higher than that of [^{68}Ga]Ga-LW02080 with 87.4 ± 5.34% remaining intact ($p < 0.01$). No intact tracer was detected in urine samples collected at 15 min pi for either [^{68}Ga]Ga-LW02060 or [^{68}Ga]Ga-LW02080.

Figure 7. Representative radio-HPLC chromatograms from analysis of intact fraction of [^{68}Ga]Ga-LW02060 in mouse (A) plasma and (B) urine samples collected at 15 min pi. The black arrow points to the peak of intact [^{68}Ga]Ga-LW02060.


Figure 8. Representative radio-HPLC chromatograms from analysis of intact fraction of [^{68}Ga]Ga-LW02080 in mouse (A) plasma and (B) urine samples collected at 15 min pi. The black arrow points to the peak of intact [^{68}Ga]Ga-LW02080.

2.5. SPECT Imaging and Ex Vivo Biodistribution

The longitudinal SPECT/CT images of [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080 were acquired at 1, 4, 24, 72, and 120 h pi (Figure 9). [^{177}Lu]Lu-LW02060 enabled clear visualization of the

PC-3 tumor xenograft in the SPECT images up to 24 h pi, while [177Lu]Lu-LW02080 can be used to clearly visualize the PC-3 tumor xenograft only at 1 h pi. Both [177Lu]Lu-LW02060 and [177Lu]Lu-LW02080 were excreted mainly via the renal pathway. Co-injection with 100 µg of [D-Phe6,Leu-NHEt13,des-Met14]Bombesin(6-14) significantly decreased the uptake of [177Lu]Lu-LW02060 and [177Lu]Lu-LW02080 in PC-3 tumor xenografts at 1 h pi.


Figure 9. Longitudinal SPECT/CT images of (A) [177Lu]Lu-LW02060 and (B) [177Lu]Lu-LW02080 in PC-3 tumor-bearing NRG mice. Acquisition time points were 1, 4, 24, 72, and 120 h pi. The blocked mice were co-injected with 100 µg of [D-Phe6,Leu-NHEt13,des-Met14]Bombesin(6-14). t: tumor; bl: urinary bladder.

The ex vivo biodistribution results of [177Lu]Lu-LW02060 and [177Lu]Lu-LW02080 were consistent with the observations from the SPECT images (Figures 9 and 10 and Tables S5-S6). The tumor uptake values of [177Lu]Lu-LW02060 were 9.59 ± 3.37, 8.38 ± 0.19, and 5.78 ± 0.40 %ID/g at 1, 4, and 24 h pi, respectively, and then dropped to < 3 %ID/g after 72 h pi. By contrast, the tumor uptake of [177Lu]Lu-LW02080 was only 5.67 ± 1.02 %ID/g at 1 h pi and decreased quickly to 2.96 ± 0.37 %ID/g at 4 h pi and < 1 %ID/g after 72 h pi (Figure 10A). The pancreas uptake of [177Lu]Lu-LW02060 were 2.64 ± 0.63, 1.71 ± 0.08, and 1.04 ± 0.19 %ID/g at 1, 4, and 24 h pi, respectively, while [177Lu]Lu-LW02080 showed markedly lower pancreas uptake (< 0.5 %ID/g for all time points) (Figure 10B). The kidney uptake values of [177Lu]Lu-LW02060 were 3.62 ± 0.86, 2.85 ± 0.29, and 1.06 ± 0.22 %ID/g at 1, 4, and 24 h pi, respectively, and slightly lower kidney uptake values were obtained from [177Lu]Lu-LW02080 (2.65 ± 0.48, 1.88 ± 0.35, and 0.89 ± 0.28 %ID/g at 1, 4, and 24 h pi, respectively). Uptake values of [177Lu]Lu-LW02060 and [177Lu]Lu-LW02080 for all other collected organs/tissues were < 1 %ID/g at all time points (Tables S5-S6).

Figure 10. Uptake of [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080 in (A) PC-3 tumor xenografts and (B) pancreas at 1, 4, 24, 72, and 120 h pi. Error bars indicate standard deviation (n = 5).

Co-injection with 100 μg of [D-Phe^6,Leu-NHEt^{13},des-Met^{14}]Bombesin(6-14) reduced the tumor uptake of [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080 at 1 h pi by 66% and 64%, respectively. For [^{177}Lu]Lu-LW02060, significant uptake reductions were also observed for pancreas, stomach, and small intestine by 81%, 72% and 66%, respectively, with co-injection of the blocking agent. By contract, for [^{177}Lu]Lu-LW02080, no significant uptake change was observed for the pancreas ($p >$ 0.05), but a slightly higher uptake was found in stomach and small intestine with co-injection of the blocking agent. No significant difference in kidney uptake of [^{177}Lu]Lu-LW02060 was observed without/with co-injection of [D-Phe^6,Leu-NHEt^{13},des-Met^{14}]Bombesin(6-14), while a significant increase in the kidney uptake of [^{177}Lu]Lu-LW02080 (from 2.65 ± 0.48 %ID/g to 4.17 ± 0.95 %ID/g, $p <$ 0.05) was observed.

2.6. Radiation Dosimetry

The calculated radiation doses absorbed by selected mouse organs/tissues from [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080 are provided in Figure 11 and Tables S7-S8. A higher radiation absorbed dose of [^{177}Lu]Lu-LW02060 was delivered to the PC-3 tumor xenografts (Unit Density Sphere Model) compared with that of [^{177}Lu]Lu-LW02080 (Figure 11A). The absorbed dose of [^{177}Lu]Lu-LW02060 in a 1-g PC-3 tumor xenograft was 272 mGy/MBq, which was 5.8-fold of the tumor absorbed dose of [^{177}Lu]Lu-LW02080 (47.0 mGy/MBq) (Figure 11A and Table S7). Urinary bladder received the highest absorbed dose for both [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080 among all selected organs/tissues with 1510 and 655 mGy/MBq, respectively, followed by kidneys with 148 and 64.4 mGy/MBq, respectively (Figure 11B and Table S7). Compared with [^{177}Lu]Lu-LW02060, an overall less absorbed dose was observed for [^{177}Lu]Lu-LW02080 in all selected organs/tissues. The absorbed dose of [^{177}Lu]Lu-LW02060 in the pancreas was 118 mGy/MBq, which was around 23-fold of the pancreas absorbed dose of [^{177}Lu]Lu-LW02080 (5.03 mGy/MBq).

Figure 11. (A) Radiation absorbed doses (mGy/MBq) of [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080 to PC-3 tumor xenografts, obtained with various tumor masses but assuming the same tumor uptake (%ID) and residence time for [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080; (B) Comparison of radiation absorbed doses with the tumor sink effect correction for selected mouse organs/tissues per unit of injected activity (mGy/MBq) from [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080.

The estimated radiation absorbed doses with the tumor sink effect correction for both [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080 in an average adult male are provided in Table 1. The highest estimated absorbed dose was observed in the urinary bladder for both ^{177}Lu-labeled ligands, with 1.50E-01 and 6.51E-02 mGy/MBq, respectively. The estimated absorbed dose of [^{177}Lu]Lu-LW02060 in the pancreas (5.08E-02 mGy/MBq) was around 30 times of the pancreas absorbed dos of [^{177}Lu]Lu-LW02080 (1.69E-03 mGy/MBq). The estimated absorbed doses of [^{177}Lu]Lu-LW02060 were consistently higher than that of [^{177}Lu]Lu-LW02080 across other selected organs/tissues, ranging from 1.9-fold to 5.8-fold. The effective whole-body dose per injected radioactivity of [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080 to an adult human male were 1.16E-02 and 4.15E-03 mSv/MBq, respectively.

Table 1. Estimated radiation absorbed doses (mGy/MBq) in adult human males for [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080.

Target Organ	[^{177}Lu]Lu-LW02060	[^{177}Lu]Lu-LW02080
Adrenals	2.45E-02	4.24E-03
Brain	2.85E-04	1.04E-04
Esophagus	8.10E-04	3.14E-04
Eyes	5.72E-04	2.45E-04
Gallbladder wall	1.20E-03	4.15E-04
Left colon	2.59E-02	5.58E-03
Small intestine	7.60E-03	3.97E-03
Stomach wall	3.70E-03	1.45E-03
Right colon	1.35E-02	2.98E-03

Rectum	1.30E-02	3.00E-03
Heart	2.66E-03	1.17E-03
Kidneys	6.36E-02	2.78E-02
Liver	1.29E-02	3.17E-03
Lungs	5.31E-03	2.11E-03
Pancreas	5.08E-02	1.69E-03
Prostate	1.64E-03	6.94E-04
Salivary glands	5.91E-04	2.52E-04
Red marrow	7.68E-04	3.23E-04
Skeleton	1.04E-03	4.73E-04
Spleen	9.47E-03	2.92E-03
Testes	2.49E-03	1.05E-03
Thymus	6.92E-04	2.85E-04
Thyroid	6.38E-04	2.68E-04
Urinary bladder	1.50E-01	6.51E-02
Total body	2.55E-03	9.77E-04
Effective dose (mSv/MBq)	1.16E-02	4.15E-03

3. Discussion

Based on our previously reported LW02056 and ProBOMB5, we designed two novel DOTA-conjugated GRPR-targeted ligands, LW02060 and LW02080, by replacing Pro^{14} in LW02056 and ProBOMB5, respectively, with $diF-Pro^{14}$ (Figure 1) [24]. The data from intracellular calcium efflux assay confirm the agonist characteristics of LW02060 and its Ga/Lu-complexed analogs, and the antagonist characteristics of LW02080 and its Ga/Lu-complexed analogs (Figure 2). The agonist/antagonist characteristics of both $diF-Pro^{14}$ derivatives are aligned with their Pro^{14} analogs (LW02056 and ProBOMB5). This validates our hypothesis that $diF-Pro^{14}$ substitution on previously reported LW02056 and ProBOMB5 would retain their GRPR agonist/antagonist characteristics

The binding affinities of the Ga/Lu-complexed LW02060 analogs were better than that of LW02080, respectively (Figure 3). Compared to its Pro^{14} analog Ga-LW02056, Ga-LW02060 showed a significantly higher binding affinity to GRPR ($K_i = 14.7 \pm 4.81$ vs 5.57 ± 2.47 nM, $p < 0.05$) [24]. In contrast, the binding affinities of the GRPR antagonists, Ga-LW02080 and Lu-LW02080, were found to be lower than that of Ga-ProBOMB5 and Lu-ProBOMB5 ($K_i = 21.7 \pm 6.69$ and 32.1 ± 8.14 nM vs 12.2 ± 1.89 and 13.6 ± 0.25 nM, respectively) [24]. This observation suggests that the $diF-Pro^{14}$ substitution enhances the binding affinity of GRPR agonists (Ga-LW02060), while reducing the binding affinity of GRPR antagonists (Ga-LW02080 and Lu-LW02080). Previously, we also observed that $NMe-Gly^{11}$ substitution was tolerable for antagonists, but decreased the binding affinity of agonists [20,23]. Similarly, $NMe-His^{12}$ substitution was found to improve binding affinity for only agonists, but decrease the binding affinity for antagonists [22]. Our accumulated data suggest that agonists and antagonists bind to GRPR in different configurations.

The hydrophilic nature of [^{68}Ga]Ga-LW02060, [^{68}Ga]Ga-LW02080, [^{177}Lu]Lu-LW02060, and [^{177}Lu]Lu-LW02080 were confirmed via the $logD_{7.4}$ measurements with $logD_{7.4}$ values all ≤ -2.33. Compared with their Pro^{14} analogs ([^{68}Ga]Ga-LW02056 and [^{68}Ga]Ga-ProBOMB5), both [^{68}Ga]Ga-LW02060 and [^{68}Ga]Ga-LW02080 had significantly higher $logD_{7.4}$ values (-2.93 ± 0.08 and -2.74 ± 0.04 vs -2.57 ± 0.04 and -2.60 ± 0.03, respectively; $p < 0.01$). This suggests that replacing Pro^{14} with $diF-Pro^{14}$ slightly increases the lipophilicity of two tracers.

Both [^{68}Ga]Ga-LW02060 and [^{68}Ga]Ga-LW02080 enabled clear visualization of the PC-3 tumor xenografts in PET images at 1 h pi (Figure 4). The extremely high accumulation of both tracers in the urinary bladders seen in PET images indicates that their main excretion was via the renal pathway, likely resulting from the highly hydrophilic nature of both tracers. The ex vivo biodistribution data of [^{68}Ga]Ga-LW02060 and [^{68}Ga]Ga-LW02080 were consistent with the observations from their PET images (Figures 4–6 and Table S4). Possibly owing to its higher binding affinity, [^{68}Ga]Ga-LW02060

exhibited 2.3-fold uptake in PC-3 tumor xenografts when compared to that of [68Ga]Ga-LW02080 (16.8 ± 2.70 vs 7.36 ± 1.13 %ID/g), and 1.9-fold uptake when compared to the previously reported [68Ga]Ga-LW02056 (16.8 ± 2.70 vs 8.93 ± 1.96 %ID/g) [24]. On the other hand, compared with [68Ga]Ga-ProBOMB5, the diF-Pro14-derived [68Ga]Ga-LW02080 showed a significantly lower tumor uptake (7.36 ± 1.13 vs 12.4 ± 1.35 %ID/g, $p < 0.005$), likely due to the inferior GRPR binding affinity of Ga-LW02080 [24].

To avoid the potential toxicity caused by injecting an excessive amount of a GRPR agonist, we conducted the blocking study of the agonist tracer, [68Ga]Ga-LW02060, by co-injection with 100 μg of a GRPR antagonist, [D-Phe6,Leu-NHEt13,des-Met14]Bombesin(6-14) (Figures 4 and 6, and Table S4). For the antagonist tracer, [68Ga]Ga-LW02080, the blocking study was conducted with the co-injection of its nonradioactive standard, Ga-LW02080 (100 μg) (Figures 4 and 6, and Table S4). With a significantly reduced tumor uptake in the blocked mice, both blocking studies confirmed the specific uptake of [68Ga]Ga-LW02060 and [68Ga]Ga-LW02080 in the GRPR-expressing PC-3 tumor xenografts. The increased background uptake especially in the kidneys of blocked mice was mainly resulted from competitive binding of blocking agents to the GRPR in PC-3 tumor xenografts, leading to more unbound [68Ga]Ga-LW02060 and [68Ga]Ga-LW02080 in the blood pool and to be excreted through the renal pathway.

The in vivo stability of [68Ga]Ga-LW02060 and [68Ga]Ga-LW02080 was assessed at 15 min pi (Figures 7 and 8). More than 99% of [68Ga]Ga-LW02060 remained intact in mouse plasma, which was significantly higher than that of [68Ga]Ga-LW02080 (87.4 ± 5.34%) and our previously reported GRPR-targeted tracers (12.7% - 92.9%) [20–24]. The excellent in vivo stability of [68Ga]Ga-LW02060 likely contributes to its high tumor uptake (16.8 ± 2.70 at 1 h pi). Same as most of the previously reported GRPR-targeted radioligands, no intact tracer was observed in mouse urine samples, likely due to degradation by NEP which is expressed abundantly in the kidneys [18–24].

Subsequently, we labeled LW02060 and LW02080 with Lu-177 and evaluated the therapeutic potential of their 177Lu-labeled analogs via SPECT/CT imaging, ex vivo biodistribution studies, and dosimetry calculations. The longitudinal SPECT/CT images showed that compared with [177Lu]Lu-LW02060, [177Lu]Lu-LW02080 had a lower tumor uptake and was cleared faster from the PC-3 tumor xenograft (Figure 9). This is likely due to the combination of its inferior GRPR binding affinity and being an antagonist (lack of internalization upon binding to GRPR) [1,29,30]. The observations from the SPECT/CT images were confirmed by data from ex vivo biodistribution studies (Figure 10 and Tables S5-S6). The tumor uptake of [177Lu]Lu-LW02060 and [177Lu]Lu-LW02080 at 1 h pi were lower than that of their 68Ga-labeled analogs, [68Ga]Ga-LW02060 and [68Ga]Ga-LW02080 (9.59 ± 3.37 and 5.67 ± 1.02 %ID/g vs 16.8 ± 2.70 and 7.36 ± 1.13 %ID/g, respectively). The inferior tumor uptake for the 177Lu-labeled analogs could be due to their slightly inferior GRPR binding affinity, possibly resulting from variation in charge distribution of different DOTA-metal complexes. It has been previously reported by Fani et al. that complexation with a different metal could have a high impact on the binding affinity of a somatostatin receptor 2 (Sstr2)-targeted ligand, DOTA-JR11 [31]. While the IC50 values of Y-DOTA-JR11 and Lu-DOTA-JR11 were 0.47 and 0.73 nM, respectively, the IC50 value of Ga-DOTA-JR11 was only 29 nM. Surprisingly, with a different chelator, Ga-NODAGA-JR11 was much more potent and had IC50 value at 1.2 nM, close to that of Y-DOTA-JR11 and Lu-DOTA-JR11. Therefore, we are currently investigating the effect of different chelators on the binding affinity of Ga/Lu-complexed GRPR-targeted ligands.

Owing to their dominantly renal excretion, the highest absorbed dose for both [177Lu]Lu-LW02060 and [177Lu]Lu-LW02080 was received by the urinary bladder in the mouse model. The calculated absorbed dose of [177Lu]Lu-LW02060 in a 1-g PC-3 tumor xenograft was 272 mGy/MBq, which was 5.8-fold of that of [177Lu]Lu-LW02080 (47.0 mGy/MBq) and 4.7-fold of the tumor absorbed dose of our previously reported [177Lu]Lu-ProBOMB5 (57.3 mGy/MBq) [24]. However, the absorbed dose of the clinical validated GRPR antagonist [177Lu]Lu-RM2 in the same tumor model was 429 mGy/MBq, which is 1.6-fold of that of [177Lu]Lu-LW02060. This is due to the longer tumor retention of [177Lu]Lu-RM2, likely resulted from its higher GRPR binding affinity ($K_i = 1.19 ± 0.16$ nM) [24]. The

radiation absorbed doses delivered to the pancreas by [177Lu]Lu-LW02060 and [177Lu]Lu-LW02080 (118 and 5.03 mGy/MBq) were markedly lower than that of [177Lu]Lu-RM2 (316 mGy/MBq) [24]. Additionally, the overall lower absorbed doses of [177Lu]Lu-LW02060 and [177Lu]Lu-LW02080 in most selected organs/tissues compared to that of [177Lu]Lu-RM2 indicate less off-target binding of [177Lu]Lu-LW02060 and [177Lu]Lu-LW02080 in the mouse model.

Though compared to [177Lu]Lu-LW02080, [177Lu]Lu-LW02060 has a higher tumor uptake and a longer tumor retention, it is still not ideal for therapeutic application due to its insufficient radiation absorbed dose deposited in tumors. Further optimizations are needed to enhance tumor uptake and extend tumor retention, thereby achieving a potentially better therapeutic efficacy.

4. Materials and Methods

4.1. General Methods

All chemicals and solvents used in this study were purchased from commercial sources, and used without further purification. GRPR-targeting peptides were synthesized using solid phase approach on an AAPPTec (Louisville, KY, USA) Endeavor 90 peptide synthesizer. Purification and quality control of synthesized peptides were performed on Agilent (Santa Clara, CA, USA) HPLC systems equipped with a model 1200 quaternary pump, a model 1200 UV absorbance detector (220 nm), and a Bioscan (Washington, DC, USA) NaI scintillation detector. The operation of Agilent HPLC systems was controlled using the Agilent ChemStation software. The HPLC columns used were a semi-preparative column (Luna C18, 5 μm, 250 × 10 mm) and an analytical column (Luna C18, 5 μm, 250 × 4.6 mm) purchased from Phenomenex (Torrance, CA, USA). The collected HPLC eluates were lyophilized using a Labconco (Kansas City, MO, USA) FreeZone 4.5 Plus freeze-drier. MS spectra were acquired on an AB SCIEX (Framingham, MA, USA) 4000 QTRAP mass spectrometer system with an ESI ion source. C18 Sep-Pak cartridges (1 cm^3, 50 mg) were purchased from Waters (Milford, MA, USA). ^{68}Ga was eluted from an ITM Medical Isotopes GmbH (Munich, Germany) generator, and purified according to the previously published procedures using a DGA resin column from Eichrom Technologies LLC (Lisle, IL, USA) [32]. ^{177}LuCl$_3$ was purchased from Isotopia Molecular Imaging Ltd (Petah Tikva, Israel) and ITM Medical Isotopes GmbH (Munich, Germany). Radioactivity of ^{68}Ga/^{177}Lu-labeled peptides was measured using a Capintec (Ramsey, NJ, USA) CRC®-25R/W dose calibrator. The radioactivity of samples collected from biodistribution studies, binding assays, and logD$_{7.4}$ measurements were counted using a Perkin Elmer (Waltham, MA, USA) Wizard2 2480 automatic gamma counter.

4.2. Synthesis of Fmoc-Leu(ψ)diF-Pro-OH

Fmoc-Leu(ψ)diF-Pro-OH (**5**) was synthesized following the reaction steps depicted in Scheme S1. Detailed synthesis procedures and characterizations for Fmoc-Leu(ψ)diF-Pro-OH (**5**) and its intermediates are provided in Supplementary Materials (Figures S1-S16).

4.3. Synthesis of DOTA-Conjugated Peptides

Both LW02060 and LW02080 were synthesized on solid phase using the Fmoc peptide chemistry. For the synthesis of LW02060, Rink Amide MBHA resin (0.1 mmol) was treated with 20% piperidine in *N,N*-dimethylformamide (DMF) to remove the Fmoc protecting group. Fmoc-protected amino acids (5 eq.) and Fmoc-4-amino-(1-carboxymethyl)piperidine (5 eq.) were pre-activated with HATU (5 eq.), HOAt (5 eq.), and *N,N*-diisopropylethylamine (DIEA, 15 eq.) and then sequentially coupled to the resin. For the synthesis of LW02080, Sieber resin (0.1 mmol) was treated with 20% piperidine in DMF to remove the Fmoc protecting group. Fmoc-Leu(ψ)diF-Pro-OH (**5**) (5 eq.), Fmoc-protected amino acids (5 eq.), and Fmoc-4-amino-(1-carboxymethyl)piperidine (5 eq.) were pre-activated with HATU (5 eq.), HOAt (5 eq.), and DIEA (15 eq.), and then sequentially coupled to the resin. At the

end, DOTA(*t*Bu)₃ (5 eq.) pre-activated with HATU (5 eq.) and DIEA (25 eq.) was coupled to the resin for both LW02060 and LW02080.

The peptides were deprotected and simultaneously cleaved from the resin with a mixture of trifluoroacetic acid (TFA, 81.5%), triisopropylsilane (TIS 1.0%), water (5%), 2,2′-(ethylenedioxy)diethanethiol (DODT, 2.5%), thioanisole (5%), and phenol (5%) for 4 h at room temperature. The cleaved peptides were filtered and precipitated by the addition of cold diethyl ether. The crude peptides were collected after centrifugation and purified with HPLC (semi-preparative column; flow rate: 4.5 mL/min). The eluates containing the desired peptides were collected and lyophilized. The HPLC conditions, retention times, isolated yields and MS confirmations of LW02060 and LW02080 are provided in Table S1 and Figures S17-S18.

4.4. Synthesis of Nonradioactive Ga/Lu-Complexed Standards

The nonradioactive Ga-complexed standards of LW02060 and LW02080 were prepared by incubating a solution of the DOTA-conjugated precursor with excess GaCl₃ (5 eq.) in NaOAc buffer (0.1 M, 500 µL, pH 4.5) at 80 °C for 15 min. The nonradioactive Lu-complexed standards of LW02060 and LW02080 were synthesized by incubating a solution of the precursor with excess LuCl₃ (10 eq.) in NaOAc buffer (0.1 M, 500 µL, pH 4.5) at 90 °C for 30 min. After that, the reaction mixture was purified via HPLC (semi-preparative column, flow rate: 4.5 mL/min). The HPLC eluates containing the desired peptide were collected and lyophilized. The HPLC conditions, retention times, isolated yields and MS confirmations of these nonradioactive Ga/Lu-complexed standards are provided in Table S2 and Figures S19-S22.

4.5. Synthesis of ^{68}Ga/^{177}Lu-Labeled Ligands

The Ga-68 radiolabeling experiments were performed following previously published procedures [32–34]. Briefly, purified ^{68}Ga in 0.5 mL water was added into a 4-mL glass vial preloaded with 0.7 mL of HEPES buffer (2 M, pH 5.0) and 10 µL precursor solution (1 mM). The radiolabeling reaction was carried out under microwave heating for 1 min at 100 ℃, followed by HPLC purification using the semi-preparative column.

The Lu-177 radiolabeling experiments were conducted following literature procedures [35]. ^{177}LuCl₃ was added into a 4-mL glass vial preloaded with 0.7 mL of NaOAc buffer (0.1 M, pH 4.5) and 10 µL precursor solution (1 mM), and incubated at 95 ℃ for 15 min with a heating block. ^{177}Lu-labeled ligands were purified by HPLC using the semi-preparative column.

The eluate fraction containing the radiolabeled product was collected, diluted with water (50 mL), and passed through a C18 Sep-Pak cartridge that was pre-washed with ethanol (10 mL) and water (10 mL). The trapped ^{68}Ga/^{177}Lu-labeled product on the cartridge was eluted off with ethanol (0.4 mL), and diluted with PBS for imaging and biodistribution studies. The HPLC conditions and retention times for the purification and quality control of ^{68}Ga/^{177}Lu-labeled ligands are provided in Table S3.

4.6. The LogD₇.₄ Measurement

The logD₇.₄ values of ^{68}Ga/^{177}Lu-labeled ligands were measured using the previously reported shake flask method [32]. An aliquot of the ^{68}Ga/^{177}Lu-labeled ligand was added into a 15 mL falcon tube containing a mixture of n-octanol (3 mL) and DPBS (3 mL, pH 7.4). The mixture was mixed by 1-min vortexing, followed by 15-min centrifugation at 3,000 rpm. Samples of the n-octanol (1 mL) and DPBS (1 mL) layers were collected and measured in a gamma counter (n = 3). The logD₇.₄ value was calculated using the following equation:

$$logD_{7.4} = log_{10}\left[\frac{counts_{octanol\ phase}}{counts_{buffer\ phase}}\right]$$

4.7. Fluorometric Calcium Release Assay

The agonist/antagonist characteristics of LW02060, Ga-LW02060, Lu-LW02060, LW02080, Ga-LW02080, and Lu-LW02080 were determined following previously published procedures [35]. A 96-well clear bottom black plate was seeded with 5×10^4 PC-3 cells in 100 μL growth media per well 24 h prior to the assay. The loading buffer (100 μL/well) containing a calcium-sensitive dye (FLIPR Calcium 6 assay kit from Molecular Devices, San Jose, CA, USA) was added into the 96-well plate, followed by 1 h incubation at 37 °C. The plate was then transferred into a FlexStation 3 microplate reader (Molecular Devices, San Jose, CA, USA). LW02060 (50 nM), Ga-LW02060 (50 nM), Lu-LW02060 (50 nM), LW02080 (50 nM), Ga-LW02080 (50 nM), Lu-LW02080 (50 nM), [D-Phe6,Leu-NHEt13,des-Met14]Bombesin(6-14) (50 nM, antagonist control), bombesin (50 nM, agonist control), adenosine triphosphate (ATP, 50 nM, positive control), or DPBS (blank control) was added, and the fluorescent signals were acquired for 2 min (λ_{Ex} = 485 nm; λ_{Em} = 525 nm; n = 4). The relative fluorescent units (RFU = max – min) were calculated to determine the agonistic/antagonistic characteristics of the tested ligands.

4.8. In Vitro Competition Binding Assay

Inhibition constants (K_i) of GRPR-targeted ligands to GRPR were measured via in vitro competition binding assay using PC-3 cells and [125I-Tyr4]Bombesin as the radioligand following previously reported method [36]. PC-3 cells were seeded in 24-well poly-D-lysine plates at 2×10^5 cells/well 48 h prior to the assay. The growth medium was replaced with 400 μL of reaction medium (RPMI 1640 containing 2 mg/mL BSA, and 20 mM HEPES). After 1 h incubation at 37 °C, Ga-LW02060, Ga-LW02080, Lu-LW02060, and Lu-LW02080 in 50 μL reaction medium with decreasing concentrations (10 μM to 1 pM) and 50 μL of 0.01 nM [125I-Tyr4]Bombesin were added into the wells followed by incubation with moderate agitation for 1 h at 37 °C. Cells were gently washed with ice-cold PBS twice, harvested by trypsinization, and counted for radioactivity on a Perkin Elmer (Waltham, MA) Wizard2 2480 automatic gamma counter. Data were analyzed using nonlinear regression (one binding site model for competition assay) with GraphPad (San Diego, CA, USA) Prism 10 software (Version 10.1.1).

4.9. PET/CT Imaging and Ex Vivo Biodistribution

PET/CT imaging, biodistribution, and in vivo stability studies were conducted on male NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ (NRG) mice following previously published procedures [32,37]. The experiments were conducted according to the guidelines established by the Canadian Council on Animal Care and approved by Animal Ethics Committee of the University of British Columbia (protocol number A20-0113, approved on September 30th, 2022). The mice were anaesthetized and subcutaneously implanted with 5×10^6 PC-3 cells (100 μL; 1:1 PBS/Matrigel) behind the left shoulder. PET/CT imaging and biodistribution studies were performed once the tumors reached a diameter of 5-8 mm, typically after approximately 4 weeks of growth.

PET/CT imaging experiments were performed using a Siemens (Knoxville, TN, USA) Inveon micro PET/CT scanner. The mice were injected with 3-5 MBq of the 68Ga-labeled tracer through a lateral caudal tail vein under anaesthesia, followed by recovery and roaming freely in their cages. At 50 min post-injection, a 10-min CT scan was conducted first for localization, attenuation correction, and reconstructing the PET images, followed by a 10-min static PET imaging acquisition.

For ex vivo biodistribution studies, the mice were injected with the 68Ga-labeled tracer (2-4 MBq) via a lateral caudal tail vein. For blocking [68Ga]Ga-LW02060, the mice were co-injected with 100 μg of [D-Phe6,Leu-NHEt13,des-Met14]Bombesin(6-14). For blocking [68Ga]Ga-LW02080, the mice were co-injected with 100 μg of its nonradioactive standard Ga-LW02080. At 1 h pi, the mice were euthanized by CO_2 inhalation. Blood and organs/tissues of interest were collected, weighed, and counted using a gamma counter.

4.10. SPECT/CT Imaging and Ex Vivo Biodistribution

SPECT/CT imaging was conducted using an MI Labs (Houten, The Netherlands) U-SPECT-II/CT scanner with a custom-made ultra-high sensitivity big mouse collimator (2 mm pinhole size). PC-3 tumor-bearing mice were sedated (2.5% isoflurane in O_2) and injected with the ^{177}Lu-labeled ligand through a lateral caudal tail vein. The mouse was imaged at 1, 4, 24, 72, and 120 h pi. At each time point, a 5-min CT scan was obtained using 615 μA and 60 kV parameters for localization and attenuation, followed by 2 × 30-min static SPECT scans acquired in list mode with an energy window centered around 208 keV. The U-SPECT II software was used to reconstruct data, and the images were decay corrected to the time of injection with PMOD v 3.402 (PMOD Technologies GmbH, Fallanden, Switzerland).

For ex vivo biodistribution studies, the mice were injected with ~3-5 MBq of the ^{177}Lu-labeled ligand (n = 5). At 1, 4, 24, 72, and 120 h post-injection, the mice were anesthetized with 2% isoflurane, euthanized by CO_2 inhalation, and the tissues/organs of interest were corrected for radioactivity counting. The blocking study was performed at 1 h pi via co-injection of the ^{177}Lu-labeled ligand with 100 μg of [D-Phe^6,Leu-NHEt^{13},des-Met^{14}]Bombesin(6-14).

4.11. In Vivo Stability Study

For in vivo stability studies, 200 μL of [^{68}Ga]Ga-LW02060 or [^{68}Ga]Ga -LW02080 was injected into healthy male NRG mice (n = 3) tough a lateral caudal tail vein. At 15 min pi, mice were anaesthetized and euthanized followed by collection of the urine and blood samples. The plasma was extracted from whole blood by adding an equal volume of CH_3CN, followed by vortexing, centrifugation, and collection of the supernatant. The plasma and urine samples were analyzed via radio-HPLC.

4.12. Dosimetry Analysis

The uptake values (%ID/g) obtained from ex vivo biodistribution studies (n = 5) were decayed corrected to the appropriate time point and fitted to mono- or bi-exponential equations using SciPy library integrated into an in-house Python script (Python Software Foundation v.3.10.12) [38]. The best fit was selected based on maximizing the coefficient of determination (R^2) and minimizing the residuals. Time–activity curves calculated from the parameters obtained from the best fit for each organ were then integrated and normalized to injected activity to acquire time-integrated activity coefficients (TIACs) per unit gram, and subsequently multiplied by the mass of model tissue (30-g mouse phantom) [39]. The TIACs were corrected for tumor sink effect following formula adopted in the report by Cicone et al. [40] as shown below:

$$TIAC_{m,corrected}(organ) = TIAC_m(organ) + \left[TIAC_m(tumor) \times \frac{TIAC_m(organ)}{TIAC_m(WB) - TIAC_m(tumor)} \right]$$

The TIAC values were input into OLINDA (Hermes Medical Solutions, v2.2.3) software [41] which has pre-calculated dose factors for mouse models. Mouse biodistribution data were extrapolated to humans using the method proposed by Kirschner, et al. using the following equation [42]:

$$TIAC_H(organ) = TIAC_M(organ) \times \left[\frac{m(organ)_H / WB_H}{m(organ)_M / WB_M} \right]$$

where m(organ)$_H$ and m(organ)$_M$ are masses of human and mouse organs, respectively, and *WB* represents total-body mass. Human TIACs calculated with the above equation were input into OLINDA and dosimetry results were assessed for ICRP 89 Adult Male Model [43]. The %ID/g value for the blood was assumed to be that for the heart contents of the phantom. Lastly, the TIAC for the tumor was also calculated on the basis of the biodistribution data, and the values were input into the sphere model available in OLINDA [44].

4.13. Statistical Analysis

Statistical analyses were performed via Student's *t*-test using the Microsoft (Redmond, WA, USA) Excel software. The unpaired two-tailed test was used to compare biodistribution data, binding affinities, and logD$_{7.4}$ values of two radioligands. The unpaired one-tailed test was used to compare

the biodistribution data of unblocked mice with that of blocked mice. Statistically significant difference was considered when the adjusted *p* value was < 0.05.

5. Conclusions

We synthesized two novel GRPR-targeted ligands, LW02060 and LW02080, by replacing Pro[14] in previously reported LW02056 (an agonist) and ProBOMB5 (an antagonist), respectively, with diF-Pro[14]. Our study reveals that the diF-Pro[14] substitution retains their agonist/antagonist characteristics. The diF-Pro[14] substitution on the agonist sequence further improves binding affinity and in vivo stability. By contrast, the diF-Pro[14] substitution significantly reduces the binding affinity of the antagonist ligand which has a reduced peptide bond (CH_2-N) between Leu[13] and AA[14]. Consistent with the low pancreas uptake of their previously reported Pro[14] analogs, both [^{68}Ga]Ga-LW02060, and [^{68}Ga]Ga-LW02080 showed low pancreas uptake compared to the clinically evaluated GRPR-targeted tracers. With high in vivo stability, great tumor uptake and excellent tumor-to-background imaging contrast, [^{68}Ga]Ga-LW02060 is a promising tracer for clinical translation to detect GRPR-expressing cancer.

In addition, we successfully labeled both GRPR-targeted ligands with Lu-177 and evaluated the therapeutic potential of resulting [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080. However, moderate tumor uptake and rapid clearance from PC-3 tumor xenografts were observed for both [^{177}Lu]Lu-LW02060 and [^{177}Lu]Lu-LW02080, resulting in low radiation absorbed doses delivered to tumors. Thus, further optimizations are still needed for both ligands to enhance tumor uptake and extend tumor retention for potential therapeutic applications.

6. Patents

The compounds disclosed in this report are covered by a recent patent application (PCT International Application Serial No. PCT/CA2024/051215; filing date: September 13, 2024). Lei Wang, Chao-Cheng Chen, François Bénard and Kuo-Shyan Lin are listed as inventors of this filed patent.

A.A.W.L.W., S.K. and W.S.L.; investigation, L.W., C.-C.C., D.C., A.A.W.L.W., S.K., and K.-S.L.; resources, C.U., F.B., and K.-S.L.; data curation, L.W. and K.-S.L.; writing—original draft preparation, L.W.; writing—review and editing, K.-S.L.; visualization, L.W.; supervision, C.U., K.-S.L., and F.B.; project administration, K.-S.L.; funding acquisition, C.U., K.-S.L. and F.B. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement: The animal study protocol (A20-0113) was approved by the Animal Ethics Committee of the University of British Columbia on September 30th, 2022.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the Supplementary Materials.

Conflicts of Interest: François Bénard and Kuo-Shyan Lin are co-founders and consultants of Alpha-9 Oncology Inc., and receive research funding from the company. Devon Chapple is a part-time employee of Alpha-9. François Bénard and Kuo-Shyan Lin hold shares and/or options in Alpha-9, and the company has licensed a patent application related to subject matter contained in this manuscript.

References

1. Jensen, R.; Battey, J.; Spindel, E.; Benya, R., International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. *Pharmacol. Rev.* **2008,** *60*, 1-42.

2. Weber, H. C., Regulation and signaling of human bombesin receptors and their biological effects. *Curr. Opin. Endocrinol., Diabetes Obes.* **2009,** *16*, 66-71.

3. Cornelio, D. B.; Roesler, R.; Schwartsmann, G., Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. *Ann. Oncol.* **2007,** *18*, 1457-1466.

4. Markwalder, R.; Reubi, J. C., Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. *Cancer Res.* **1999,** *59*, 1152-1159.

5. Gugger, M.; Reubi, J. C., Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. *Am. J. Pathol.* **1999,** *155*, 2067-2076.

6. Preston, S.; Woodhouse, L.; Jones-Blackett, S.; Miller, G.; Primrose, J., High-affinity binding sites for gastrin-releasing peptide on human colorectal cancer tissue but not uninvolved mucosa. *Br. J. Cancer* **1995,** *71*, 1087-1089.

7. Mattei, J.; Achcar, R. D.; Cano, C. H.; Macedo, B. R.; Meurer, L.; Batlle, B. S.; Groshong, S. D.; Kulczynski, J. M.; Roesler, R.; Dal Lago, L., Gastrin-releasing peptide receptor expression in lung cancer. *Arch. Pathol. Lab. Med.* **2014,** *138*, 98-104.

8. Shriver, S. P.; Bourdeau, H. A.; Gubish, C. T.; Tirpak, D. L.; Davis, A. L. G.; Luketich, J. D.; Siegfried, J. M., Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. *J. Natl. Cancer Inst.* **2000,** *92*, 24-33.

9. Kurth, J.; Krause, B. J.; Schwarzenböck, S. M.; Bergner, C.; Hakenberg, O. W.; Heuschkel, M., First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [^{177}Lu]Lu-RM2: A radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. *Eur. J. Nucl. Med. Mol. Imaging* **2020,** *47*, 123-135.

10. Nock, B. A.; Kaloudi, A.; Lymperis, E.; Giarika, A.; Kulkarni, H. R.; Klette, I.; Singh, A.; Krenning, E. P.; de Jong, M.; Maina, T., Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results. *J. Nucl. Med.* **2017,** *58*, 75-80.

11. Varvarigou, A.; Bouziotis, P.; Zikos, C.; Scopinaro, F.; De Vincentis, G., Gastrin-releasing peptide (GRP) analogues for cancer imaging. *Cancer Biother. Radiopharm.* **2004,** *19*, 219-229.

12. Baum, R.; Prasad, V.; Mutloka, N.; Frischknecht, M.; Maecke, H.; Reubi, J., Molecular imaging of bombesin receptors in various tumors by Ga-68 AMBA PET/CT: First results. *J. Nucl. Med.* **2007,** *48*, 79.

13. Kähkönen, E.; Jambor, I.; Kemppainen, J.; Lehtiö, K.; Grönroos, T. J.; Kuisma, A.; Luoto, P.; Sipilä, H. J.; Tolvanen, T.; Alanen, K., In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. *Clin. Cancer Res.* **2013,** *19*, 5434-5443.

14. Marsouvanidis, P. J.; Maina, T.; Sallegger, W.; Krenning, E. P.; de Jong, M.; Nock, B. A., 99mTc radiotracers based on human GRP (18-27): synthesis and comparative evaluation. *J. Nucl. Med.* **2013,** *54*, 1797-1803.

15. Reile, H.; Cai, R.; Armatis, P.; Schally, A., New antagonists of bombesin gastrin-releasing peptide with C-terminal Leu-psi-(CH2N)Tac-NH2. *Int. J. Oncol.* **1995,** *7*, 749-754.

16. Cai, R.; Reile, H.; Armatis, P.; Schally, A. V., Potent bombesin antagonists with C-terminal Leu-psi-(CH2N)Tac-NH2 or its derivatives. *Proc. Natl. Acad. Sci.* **1994,** *91*, 12664-12668.

17. Minamimoto, R.; Hancock, S.; Schneider, B.; Chin, F. T.; Jamali, M.; Loening, A.; Vasanawala, S.; Gambhir, S. S.; Iagaru, A., Pilot comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer. *J. Nucl. Med.* **2016,** *57*, 557-562.

18. Chatalic, K. L.; Konijnenberg, M.; Nonnekens, J.; de Blois, E.; Hoeben, S.; de Ridder, C.; Brunel, L.; Fehrentz, J.-A.; Martinez, J.; van Gent, D. C., In vivo stabilization of a gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies. *Theranostics* **2016,** *6*, 104.

19. Nock, B. A.; Maina, T.; Krenning, E. P.; de Jong, M., "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting. *J. Nucl. Med.* **2014,** *55*, 121-127.

20. Wang, L.; Zhang, Z.; Merkens, H.; Zeisler, J.; Zhang, C.; Roxin, A.; Tan, R.; Bénard, F.; Lin, K.-S., 68Ga-labeled [Leu13ψThz14]Bombesin(7–14) derivatives: promising GRPR-targeting PET tracers with low pancreas uptake. *Molecules* **2022,** *27*, 3777.

21. Wang, L.; Bratanovic, I. J.; Zhang, Z.; Kuo, H.-T.; Merkens, H.; Zeisler, J.; Zhang, C.; Tan, R.; Bénard, F.; Lin, K.-S., 68Ga-Labeled [Thz14]Bombesin(7–14) analogs: promising GRPR-targeting agonist PET tracers with low pancreas uptake. *Molecules* **2023,** *28*, 1977.

22. Wang, L.; Kuo, H.-T.; Zhang, Z.; Zhang, C.; Chen, C.-C.; Chapple, D.; Wilson, R.; Colpo, N.; François Bénard; Lin, K.-S., Unnatural amino acid substitutions to improve in vivo stability and tumor uptake of 68Ga-labeled GRPR-targeted TacBOMB2 derivatives for cancer imaging with positron emission tomography. *EJNMMI Radiopharmacy and Chem.* **2024,** *9*, 8.

23. Wang, L.; Chen, C.-C.; Zhang, Z.; Kuo, H.-T.; Zhang, C.; Colpo, N.; Merkens, H.; Bénard, F.; Lin, K.-S., Synthesis and evaluation of novel 68Ga-Labeled [D-Phe6,Leu13ψThz14]bombesin(6-14) analogs for cancer imaging with positron emission tomography *Pharmaceuticals* **2024,** *17*, 621.

24. Wang, L.; Kuo, H.-T.; Chapple, D. E.; Chen, C.-C.; Kurkowska, S.; Colpo, N.; Uribe, C.; Bénard, F.; Lin, K.-S., Synthesis and evaluation of 68Ga- and 177Lu-Labeled [Pro14]bombesin(8–14) derivatives for detection and radioligand therapy of gastrin-releasing peptide receptor-expressing cancer. *Mol. Pharmaceutics* **2024,** *21*, 6385-6397.

25. Jeffries, B.; Wang, Z.; Felstead, H. R.; Le Questel, J.-Y.; Scott, J. S.; Chiarparin, E.; Graton, J.; Linclau, B., Systematic investigation of lipophilicity modulation by aliphatic fluorination motifs. *J. Med. Chem.* **2020,** *63*, 1002-1031.

26. Mykhailiuk, P. K., Fluorine-containing prolines: synthetic strategies, applications, and opportunities. *J. Org. Chem.* **2022,** *87*, 6961-7005.

27. Jansen, K.; Heirbaut, L.; Verkerk, R.; Cheng, J. D.; Joossens, J.; Cos, P.; Maes, L.; Lambeir, A.-M.; De Meester, I.; Augustyns, K.; Van der Veken, P., Extended structure–activity relationship and pharmacokinetic investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP). *J. Med. Chem.* **2014,** *57*, 3053-3074.

28. Li, M.; Younis, M. H.; Zhang, Y.; Cai, W.; Lan, X., Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. *Eur. J. Nucl. Med. Mol. Imaging* **2022,** *49*, 2844-2868.

29. Mansi, R.; Fleischmann, A.; Mäcke, H. R.; Reubi, J. C., Targeting GRPR in urological cancers—from basic research to clinical application. *Nat. Rev. Urol.* **2013,** *10*, 235-244.

30. Yang, M.; Gao, H.; Zhou, Y.; Ma, Y.; Quan, Q.; Lang, L.; Chen, K.; Niu, G.; Yan, Y.; Chen, X., 18F-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging. *Theranostics* **2011,** *1*, 220.

31. Fani, M.; Braun, F.; Waser, B.; Beetschen, K.; Cescato, R.; Erchegyi, J.; Rivier, J. E.; Weber, W. A.; Maecke, H. R.; Reubi, J. C., Unexpected sensitivity of sst_2 antagonists to N-terminal radiometal modifications. *J. Nucl. Med.* **2012**, *53*, 1481-1489.

32. Lin, K.-S.; Pan, J.; Amouroux, G.; Turashvili, G.; Mesak, F.; Hundal-Jabal, N.; Pourghiasian, M.; Lau, J.; Jenni, S.; Aparicio, S., In vivo radioimaging of bradykinin receptor B1, a widely overexpressed molecule in human cancer. *Cancer Res.* **2015**, *75*, 387-393.

33. Amouroux, G.; Pan, J.; Jenni, S.; Zhang, C.; Zhang, Z.; Hundal-Jabal, N.; Colpo, N.; Liu, Z.; Benard, F.; Lin, K.-S., Imaging bradykinin B1 receptor with ^{68}Ga-labeled [des-Arg^{10}] kallidin derivatives: effect of the linker on biodistribution and tumor uptake. *Mol. Pharmaceutics* **2015**, 12, (8), 2879-2888.

34. Lin, K.-S.; Amouroux, G.; Pan, J.; Zhang, Z.; Jenni, S.; Lau, J.; Liu, Z.; Hundal-Jabal, N.; Colpo, N.; Bénard, F., Comparative studies of three ^{68}Ga-labeled [des-Arg^{10}] kallidin derivatives for imaging bradykinin B1 receptor expression with PET. *J. Nucl. Med.* **2015**, *56*, 622-627.

35. Bratanovic, I. J.; Zhang, C.; Zhang, Z.; Kuo, H. T.; Colpo, N.; Zeisler, J.; Merkens, H.; Uribe, C.; Lin, K.-S.; Bénard, F., A radiotracer for molecular imaging and therapy of gastrin-releasing peptide receptor–positive prostate cancer. *J. Nucl. Med.* **2022**, *63*, 424-430.

36. Lau, J.; Rousseau, E.; Zhang, Z.; Uribe, C. F.; Kuo, H.-T.; Zeisler, J.; Zhang, C.; Kwon, D.; Lin, K.-S.; Bénard, F., Positron emission tomography imaging of the gastrin-releasing peptide receptor with a novel bombesin analogue. *ACS omega* **2019**, *4*, 1470-1478.

37. Kuo, H.-T.; Pan, J.; Zhang, Z.; Lau, J.; Merkens, H.; Zhang, C.; Colpo, N.; Lin, K.-S.; Benard, F., Effects of linker modification on tumor-to-kidney contrast of ^{68}Ga-labeled PSMA-targeted imaging probes. *Mol. Pharmaceutics* **2018**, *15*, 3502-3511.

38. Virtanen, P.; Gommers, R.; Oliphant, T. E.; Haberland, M.; Reddy, T.; Cournapeau, D.; Burovski, E.; Peterson, P.; Weckesser, W.; Bright, J., SciPy 1.0: fundamental algorithms for scientific computing in Python. *Nat. methods* **2020**, *17*, 261-272.

39. Keenan, M. A.; Stabin, M. G.; Segars, W. P.; Fernald, M. J., RADAR realistic animal model series for dose assessment. *J. Nucl. Med.* **2010**, *51*, 471-476.

40. Cicone, F.; Denoël, T.; Gnesin, S.; Riggi, N.; Irving, M.; Jakka, G.; Schaefer, N.; Viertl, D.; Coukos, G.; Prior, J. O., Preclinical evaluation and dosimetry of [^{111}In]CHX-DTPA-scFv78-Fc targeting endosialin/tumor endothelial marker 1 (TEM1). M*ol. Imaging Biol.* **2020**, *22*, 979-991.

41. Stabin, M. G.; Sparks, R. B.; Crowe, E., OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. *J. Nucl. Med.* **2005**, *46*, 1023-1027.

42. Kirschner, A.; Ice, R.; Beierwaltes, W., Radiation dosimetry of ^{131}I-19-iodocholesterol. *J. Nucl. Med.* **1973**, *14*, 713-717.

43. Stabin, M. G.; Xu, X. G.; Emmons, M. A.; Segars, W. P.; Shi, C.; Fernald, M. J., RADAR reference adult, pediatric, and pregnant female phantom series for internal and external dosimetry. *J. Nucl. Med.* **2012**, *53*, 1807-1813.

44. Stabin, M. G.; Konijnenberg, M. W., Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. *J. Nucl. Med.* **2000**, *41*, 149-160.